FAST × ASA Angelman Syndrome Clinical Trials Webinar: Europe/UK Sites, Eligibility, and How to Join Trials

FAST and the Angelman Syndrome Alliance (ASA)  co-hosted a United Kingdom/Europe-focused session that brought families and scientists together with two companies developing antisense oligonucleotide (ASO) approaches for Angelman syndrome, Ultragenyx and Ionis Pharmaceuticals. The goal was simple: share clear status updates, set expectations for UK/EU participation, and make it easier for families to navigate trials. 

This first formal collaboration combined FAST’s global, trial-focused approach with ASA’s Europe-wide research network to give UK/EU families a neutral, practical forum for side-by-side program updates—and set the stage for future joint sessions. 

What to do next 

1. Talk to your clinician about trials and whether they fit your child’s situation. 

2. Check ClinicalTrials.gov for site status and inclusion criteria for ASPIRE (GTX-102) and REVEAL (ION582).  

3. Register for a virtual pass to the FAST Global Science Summit (7–8 Nov 2025). 

   1. Direct updates from researchers and program leads, explained for families 

   2. Practical trial know-how: eligibility basics, site timelines, and visit expectations 

   3. Sessions for different stages (newly diagnosed → teens/adults) 

   4. Live translation/captioning and on-demand replay for UK/EU time zones 

   5. No travel hurdles: attend without U.S. visas, flights, or childcare logistics